Alembic Pharma USFDA inspection ends with 2 notes (2026)

What happened at the Karakhadi facility

Alembic Pharmaceuticals said the US Food and Drug Administration (USFDA) has completed a current Good Manufacturing Practices (cGMP) inspection at the company’s Karakhadi facility in Vadodara, Gujarat. The inspection was conducted from February 9 to February 18, 2026. At the end of the visit, the USFDA issued a Form 483 with two observations. Alembic told investors it plans to respond to the regulator within the stipulated timelines. The development matters because USFDA outcomes can influence product approvals, compliance standing, and continuity of supplies to the US market.

Why Form 483 observations are closely tracked

A Form 483 is typically issued when investigators observe conditions that may be in violation of cGMP requirements. The document lists observations that the regulator expects the company to address through a written response and corrective and preventive actions. The article notes that when issues are observed, inspectors usually file an FDA 483 form with citations. It also highlights that in more serious cases, the regulator can issue warning letters or even ban the import of drugs from the facility. The Karakhadi inspection outcome, as reported, is limited to two observations on Form 483. There is no mention of a warning letter or any import alert in the provided information.

Stock reaction: Alembic shares dip after inspection outcome

The market reaction was negative immediately after the update. Alembic Pharmaceuticals fell 1.26% to Rs 766.50 after the USFDA completed the inspection of the Karakhadi facility and issued the Form 483 with two observations. Such reactions are common in the Indian pharma sector when US regulatory observations are disclosed, as investors watch for the nature of observations and the speed of remediation. In this case, the company has only said it will respond within timelines. The report does not specify what the two observations relate to.

Company response and next procedural steps

Alembic said it will respond to the USFDA within the stipulated timelines. A company response generally includes a root-cause assessment and a corrective action plan, along with evidence or timelines for completion. The article does not provide details of Alembic’s response content for Karakhadi beyond the stated intention to reply on time. There is also no guidance in the provided text on when the regulator may conclude the matter. Outcomes after a Form 483 can vary, depending on the adequacy of the company’s corrective actions and the regulator’s review.

Context: Panelav API facility inspection in May 2025

The provided material also includes a separate exchange communication about another Alembic site. Alembic informed exchanges that the USFDA conducted an unannounced and routine cGMP inspection at its API-I & II facility at Panelav from May 26, 2025 to May 31, 2025. That inspection concluded with a Form 483 carrying four observations. The company stated that none of those observations were related to data integrity and that management believed they were addressable. Alembic also said it would provide a comprehensive response within the stipulated period. This background is relevant because it shows the company has dealt with multiple USFDA inspections across facilities.

Context: Bioequivalence facility inspection in March 2025

Another earlier inspection referenced in the text concerns Alembic’s bioequivalence facility in Vadodara. The USFDA conducted a scheduled inspection at this facility from March 3 to March 7, 2025. The inspection concluded with a Form 483 containing one procedural observation, as per the exchange filing cited. Reports in the provided text also describe the market reaction: Alembic shares declined by 2.6% following the conclusion of that scheduled inspection, and another cited market report mentioned the stock down 2.8% to 821.1 rupees around the same update. The company did not specify the nature of the observation in those reports.

Jarod facility received VAI classification after Nov 2024 inspection

The supplied material also notes a compliance classification for another site. Alembic said it received an Establishment Inspection Report (EIR) from the USFDA for its solid oral formulation facility (F-4) at Jarod, Vadodara. The inspection for that facility was carried out between November 14 and November 22, 2024, and the site was classified as ‘VAI’ (Voluntary Action Indicated). The text explains that a VAI classification indicates violations were discovered, but they do not require regulatory action, allowing the facility to continue selling previously approved drugs and obtain new approvals. The EIR is described as the FDA’s assessment of a facility’s GMP compliance.

Key facts table: inspections and reported observations

Market impact and why investors are focused on remediation

For Indian pharmaceutical exporters, USFDA inspection outcomes can affect approvals, supply reliability, and the risk profile of facilities that serve regulated markets. In the Karakhadi case, the only disclosed regulatory output is a Form 483 with two observations, and Alembic has committed to respond within timelines. The immediate share price decline to Rs 766.50, down 1.26%, reflects how quickly compliance updates can influence sentiment, even when the observations are not detailed publicly. The broader context in the provided text shows Alembic has had multiple inspection outcomes in a short period, ranging from a single procedural observation at the bioequivalence site to four observations at the Panelav API facility and a VAI classification at Jarod. Investors typically monitor whether responses are submitted on time and whether the regulator escalates matters beyond a Form 483.

Conclusion

Alembic Pharmaceuticals’ Karakhadi facility inspection ended with a Form 483 carrying two observations after a USFDA cGMP visit held from February 9 to February 18, 2026. The company has said it will respond within the stipulated timelines. The stock slipped 1.26% to Rs 766.50 following the disclosure. The next confirmed step, based on the company’s statement, is the submission of Alembic’s formal response to the USFDA within the required timeframe.